This notwithstanding, our findings suggest that targeting the NF-κB pathway through GADD45β would provide an effective means to counter oncogenesis by reversing TME-mediated immunosuppression and, concurrently, inducing cancer-cell apoptosis, thereby providing dual therapeutic benefit (Fig. 1). The gene discussed is GADD45B; the disease is cancer.